Bear bile powder induces apoptosis of human hepatocellular carcinoma cells via mitochondrion-dependent pathway

Chinese Journal of Integrative Medicine

Volumn 20, Issue 2, 2014, Pages 123-129

  Zhao, Jin Yan ^a,b   Chen, Zhi Hong ^c   Lin, Wei ^a   Zhong, Xiao Yong ^a   Chen, Xu Zheng ^a   Peng, Jun ^a   Hong, Zhen Feng ^a  

^a Fujian Academy of Integrative Medicine   (China)

^b FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c Fujian Guizhentang Pharmaceutical Co Ltd   (China)

Author keywords

apoptosis; Bear Bile Powder; hepatocellular carcinoma; mitochondria

Indexed keywords

ANTINEOPLASTIC AGENT; BEAR BILE POWDER; BILE EXTRACT; CASPASE 3; CASPASE 9; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL GROWTH; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION DEPENDENT PATHWAY; PHASE CONTRAST MICROSCOPY; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; BILE; CARCINOMA, HEPATOCELLULAR; CASPASES; CELL PROLIFERATION; CELL SHAPE; CELL SURVIVAL; DRUGS, CHINESE HERBAL; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; SIGNAL TRANSDUCTION; URSIDAE;

EID: 84899064861     PISSN: 16720415     EISSN: 19930402     Source Type: Journal    
DOI: 10.1007/s11655-013-1581-9     Document Type: Article

References (27)

1. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008;14:4300-4308.
2. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827-841. (Pubitemid 29108856)
3. Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LA. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci 2002;963:13-20. (Pubitemid 34721691)
4. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005;25:143-154. (Pubitemid 40781067)
5. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. (Pubitemid 40372904)
6. Yeh CT, Chen TC, Chang ML, Hsu CW, Yeh TS, Lee WC, et al. Identification of NV-F virus DNA in hepatocellular carcinoma. J Med Virol 2007;79:92-96.
7. Levin, B and Amos C. Therapy of unresectable hepatocellular carcinoma. N Engl J Med 1995;332:1294-1296.
8. Abou-Alfa GK, Huitzil-Melendez FD, O'Reilly EM, Saltz LB. Current management of advanced hepatocellular carcinoma. Gastrointest Cancer Res 2008;2:64-70.
9. Boose G, Stopper H. Genotoxicity of several clinically used topoisomerase II inhibitors. Toxicol Letters 2000;116:7-16. (Pubitemid 30440762)
10. Gordaliza M. Natural products as leads to anticancer drugs. Clin Transl Oncol 2007;9:767-776.
11. Newman DJ, Cragg GM, Snader KM. The influence of natural products upon drug discovery. Nat Prod Rep 2000;17:215-234. (Pubitemid 30390787)
12. Gao XM, ed. Chinese materia medica. Bear bile. Bejing: China Chinese Medicine Publisher;2002:160-161.
13. Wang LY, Gao X, Tong ZL, Wang XG. Summary on pharmacological action and clinical study of the chemical composition of bear bile. Chin J Inform Tradit Chin Med (Chin) 2005;22:30-33.
14. Yu SZ. Pharmacological effects and clinical application of Bear bile. Lishizhen Med Mater Med Res (Chin) 2007;18:707-708.
15. Feng Y, Siu K, Wang N, Ng KM, Tsao SW, Nagamatsu T, Tong Y. Bear bile: dilemma of traditional medicinal use and animal protection. J Ethnobiol Ethnomed 2009;12:2.
16. Sheng L, Zhang ML, Li H. Clinical observation on elimination of chronic hepatitis B induced jaundice in 33 CHB patients after administrated with Xiongdan Capsule. J Clin Hepatol 1994;7:40-41.
17. Xu HB, Sun X, Wen FC, Zhou JH, Li SL, Ding T, Liu L. A survey and prospect of the research of bear bile. Chin J Inform Tradit Chin Med (Chin) 1998;5:18-20.
18. Jin Y, Wen YS, Cui YZ, Jin RH. Effects of bears' bile on the expression of tumor cell p53 protein. Chin J Integr Tradit West Med (Chin) 2006;26:86-88.
19. Cory S, Adams JM. The Bcl-2 family: regulators of the cellular life-of-death switch. Nat Rev Cancer 2002;2:647-656. (Pubitemid 37328916)
20. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007;26:1324-1337. (Pubitemid 46328466)
21. Schendel SL, Montal M, Reed JC. Bcl-2 family proteins as ion-channels. Cell Death Differ 1998;5:372-380. (Pubitemid 28356813)
22. Petros AM, Olejniczak ET, Fesik SW. Structural biology of Bcl-2 family of proteins. Biochimica et Biophysica Acta 2004;1644:83-94. (Pubitemid 38281265)
23. Peng J, Tan C, Roberts GJ, Nikolaeva O, Lapolla SM, Andrews DW, Lin J. tBid elicits a conformational alteration in membrane-bound Bcl-2 such that it inhibits Bax Pore formation. J Biol Chem 2006;281:35802-35811. (Pubitemid 46041312)
24. Peng J, Ding J, Tan C, Baggenstoss B, Zhang Z, Lapolla SM, et al. Oligomerization of membrane-bound Bcl-2 is involved in its pore formation induced by tBid. Apoptosis 2009;14:1145-1153.
25. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997;275:1132-1136. (Pubitemid 27097313)
26. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997;275:1129-1132. (Pubitemid 27097312)
27. Jürgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA 1998;95:4997-5002. (Pubitemid 28208539)